Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for an inspection at the group’s manufacturing plant located SEZ - II, Ahmedabad, from August 11, 2025 to August 14, 2025. The inspection was a Pre-Approval Inspection (PAI). The USFDA has concluded this inspection as closed. The inspection concluded with NIL observations. The EIR has classified the facility as No Action Indicated (NAI).
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1651.70 |
| Dr. Reddys Lab | 1237.95 |
| Cipla | 1211.40 |
| Zydus Lifesciences | 922.95 |
| Lupin | 2309.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: